Varespladib was originally designed for use in the treatment of cardiovascular diseases (42, –44), but has recently entered phase II clinical trials for snakebite envenoming (45) following demonstration of its ability to prevent PLA2 toxin-driven systemic envenoming pathologies in animal models (29, 30, 46, 47). Here, PLA2G2A is linked to cardiovascular disorder.